People
The People
Governance grade: B+. Independent board (10 of 12), heavily performance-linked CEO pay, no related-party transactions, and no pledging — but a 17-year CEO becoming Executive Chair, a 43-year auditor relationship with PwC, and management defying a 63% shareholder vote on written consent keep this from being a clean A. Brian Evanko's elevation to CEO on July 1, 2026 — a 28-year insider groomed through CFO and COO seats — is the cleanest aspect of the story.
Governance Grade: B+ — Independent oversight, aligned pay, orderly succession — offset by entrenched CEO/Chair model and 43-year auditor tenure.
1. The People Running This Company
CEO Shares (M)
Insider Ownership
2025 CEO Pay ($M)
CEO : Median
The five named executive officers running The Cigna Group at year-end 2025 are a mix of long-tenured insiders and one recent external hire (CFO Ann Dennison). The succession story dominates the page: David Cordani retires as CEO on July 1, 2026 after 17 years and transitions to Executive Chair; Brian Evanko, a 28-year insider with CFO and COO experience, takes over.
The succession choice — insider continuity over outside reset. Evanko has been visibly groomed since 2021: CFO → Cigna Healthcare president → COO → CEO. That makes the handover safe but signals the Board sees no need for a strategic break despite five years of underperformance versus the S&P Health Care Index. The retention of Cordani as Executive Chair — not just non-executive Chair — keeps the architect of the current strategy in the room when the new CEO sets direction.
Departures worth flagging. Eric Palmer, former CEO of Evernorth Health Services, left in April 2025 with a $5.17M severance payment — his 2025 base, EIP, and full equity grants were worth approximately $12.3M total before forfeitures. CIO Noelle Eder also departed in May 2025 and forfeited unvested equity. Two C-suite exits in one quarter — both outside the CEO succession plan — is a turnover rate worth noting in a year of strategic transition.
2. What They Get Paid
CEO target compensation is 92% performance-based, with 77% in long-term equity and 100% of long-term incentives tied to performance metrics. This is genuinely shareholder-aligned pay design, not box-checking — base salary is only 8% of CEO target.
Is the pay sensible? For a $275B revenue, ~$74B market-cap company with global complexity, a $22.9M CEO package is in line with — and slightly below — peers like UnitedHealth and CVS. The pay ratio of 310:1 is unflattering but typical for the scale. More important: realized pay tracks performance. The 2023–2025 SPS award paid out at 73% of target (TSR component at 54%, EPS component at 92%) — Cordani received roughly $6.8M versus a $9.6M target value, and Compensation Actually Paid for 2023 was just $8.1M against a $21.0M reported total. The plan is doing what it's supposed to do.
What the comp plan gets right: 100% of long-term incentives are performance-based; SPS uses both relative TSR (50%) and absolute EPS (50%); 8x-base-salary stock ownership requirement for the CEO; clawback exceeds Dodd-Frank; explicit prohibition on hedging and pledging. Say-on-pay support was 89% in 2025 — strong but not unanimous.
3. Are They Aligned?
Skin-in-the-Game Score (1–10)
Score: 7/10. Cordani holds 1.20M shares worth roughly $330M at the December 31, 2025 close of $275.23 — well above the 8x base-salary requirement. Evanko holds 167K shares (~$46M). The dollar magnitude is real. But on a percentage basis, all directors and executive officers combined own only 0.6% of shares outstanding (1.67M of 263.5M). This is an institutionally-owned company — Vanguard alone owns 10.0%, BlackRock 7.6% — so the practical control sits with passive index holders, not insiders.
Ownership map
Insider activity — the pattern, not the headline
The Cigna Group does not publish parsed Form 4 data in this run, but third-party trackers and recent press summaries show the year-end 2025 / Q1 2026 picture: stock awards and option grants are the dominant transaction type; outright open-market purchases are rare; most "sales" are net-of-tax share withholding on vesting events or programmatic 10b5-1 sales. Nicole Jones sold 2,307 shares in Q1 2026 in a programmatic transaction. There is no reported insider buying signal — but also no concentrated unloading by the incoming CEO.
Capital allocation — what management does with cash
In 2025 management returned $5.2B to shareholders through buybacks and dividends, divested the Medicare Advantage business for $4.9B (a strategic narrowing), and invested $3.5B into Shields Health Solutions. Buyback pace is meaningful — diluted share count has declined steadily — and unvested-SPS dilution is capped by an explicit annual share-usage limit. The 2026 LTI design weights the per-share earnings metric to 70% of SPS (up from 50%), a deliberate tilt toward decisions that improve the metric most directly affected by repurchases.
Related-party transactions
None disclosed for 2025. The Corporate Governance Committee reviewed transactions involving directors, executives, family members, affiliated entities, and 5%+ shareholders, and concluded there were no related-person transactions requiring disclosure. The proxy notes Cigna has not adopted a written related-party transactions policy — a minor governance gap but practically de minimis here, since no transactions exist to oversee.
The legal-overhang counterweight to "no related party transactions." A self-insured client (ILWU-PMA) has sued Cigna alleging "self-dealing" through its Carewise subsidiary; a federal judge allowed the PxDx algorithmic-claims-denial class action to proceed; Express Scripts settled FTC insulin-pricing claims in February 2026; and Canada opened an antitrust probe of Express Scripts in April 2025. None of these involve directors or executives personally — but they are governance-relevant because they reflect the cost of structures the Board approved.
4. Board Quality
Ten of twelve nominees are independent. After April 1, 2026, Eric Foss replaces Eric Wiseman as Lead Independent Director; Wiseman moves to chair the Corporate Governance Committee. The Audit & Compliance Committee combines what were two committees — a structural simplification that becomes effective January 1, 2026.
Independence and expertise
Board Expertise Coverage (1=light, 5=deep)
What the board has: Two physician/PhD directors with deep healthcare-policy and health-systems credentials (McClellan was FDA Commissioner and CMS Administrator; Ozuah runs Montefiore Einstein). Strong financial expertise (Ross is former Baker Hughes / Avon CFO and Audit Committee Chair; Zarcone is a CPA and NACD-certified director). Genuine technology depth via Hathi (Schwab digital) and Kurian (NetApp CEO).
What it's thin on: Hennigan is a 2025 addition from Marathon Petroleum — energy/refining, no healthcare adjacency. The Audit & Compliance Committee for 2026 is now chaired by Ross with Hennigan, Mazzarella, McClellan, and Zarcone — financially capable but only McClellan brings healthcare-regulatory depth into audit oversight, which matters when the regulatory overhang is the single largest medium-term risk.
The governance-friction signals
Three signals worth weighing against the formal-independence narrative.
PwC has been Cigna's auditor since 1983 — 43 years. Lead-partner rotation is followed, but firm tenure of this length is well above S&P 500 medians and a reason ISS gives Cigna a Board pillar score of 4 (10 = highest concern).
The 2019 written-consent shareholder proposal received 63% support, and the board's response was to expand special-meeting rights to 25%-holders rather than honor the actual vote. The same proposal returns in 2026 and the board again recommends AGAINST. This is not necessarily wrong — but it is a clear pattern of the board choosing its own judgment over a majority shareholder vote.
Three directors have served 17+ years (Cordani 17, Wiseman 19, Zarcone 21). Cordani transitions to Executive Chair, not independent Chair, after a 17-year CEO run. Long tenure can mean institutional knowledge — or entrenchment. The Board's willingness to refresh expertise (Hennigan, Hathi, Kurian, McClellan, Ozuah are all post-2018 additions) partly mitigates this.
5. The Verdict
Final Grade: B+ — Independent, well-incentivized, and orderly — but watch the dual-control Cordani/Evanko structure and the regulatory overhang.
Alignment Score (/10)
Max Possible
Strongest positives. The compensation plan does what it says — 100% of long-term incentives are performance-based, the 2023–2025 SPS paid out at 73% (not target), and Cordani's $330M+ equity stake is substantial in dollar terms. The board is genuinely independent in composition, has refreshed five seats since 2020, and brings credible healthcare-policy and technology expertise. There are no related-party transactions, no pledging, no hedging, and no poison pill.
The real concerns. Cordani staying on as Executive Chair rather than non-executive Chair gives the outgoing CEO continuing operational influence over his hand-picked successor — an arrangement many proxy advisors flag. PwC's 43-year audit tenure is unusual, even with partner rotation. The board has twice rejected a majority-supported written-consent proposal rather than implement it. And while none of the FTC, DOJ, antitrust, or PxDx class-action matters are personal-conduct issues, they reflect the operating model the board has approved — an aggressive PBM, claims-automation, and risk-adjustment posture that is now generating regulatory friction in three jurisdictions.
What would move the grade.
- Upgrade trigger: Cordani steps off the board within 24 months of the CEO transition; Cigna rotates auditors; a majority-supported governance proposal is actually implemented. Any one of these would push the grade toward A-.
- Downgrade trigger: A material expansion of the FTC/DOJ matters, an adverse PxDx class-action ruling, or evidence that Evanko's strategy is being constrained by Executive Chair Cordani. Any of these would move the grade toward B-/C+.
For now, governance is solid enough to trust, but not so strong that it adds to the investment case. It is a feature of execution, not a competitive advantage.